Your browser doesn't support javascript.
loading
Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transition.
Zhang, Jingwei; Pearson, Adam J; Sabherwal, Nitin; Telfer, Brian A; Ali, Nisha; Kan, Karmern; Xu, Qiuping; Zhang, Wei; Chen, Fuhui; Li, Shiyang; Wang, Jinhua; Gray, Nathanael S; Risa-Ebrí, Blanca; Finegan, Katherine G; Cross, Michael J; Giurisato, Emanuele; Whitmarsh, Alan J; Tournier, Cathy.
Afiliación
  • Zhang J; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health (FBMH), University of Manchester, UK.
  • Pearson AJ; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health (FBMH), University of Manchester, UK.
  • Sabherwal N; Division of Developmental Biology and Medicine, School of Medical Sciences, FBMH, University of Manchester, UK.
  • Telfer BA; Division of Pharmacy and Optometry, School of Health Sciences, FBMH, University of Manchester, UK.
  • Ali N; Manchester University NHS FT, Wythenshawe hospital, UK.
  • Kan K; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health (FBMH), University of Manchester, UK.
  • Xu Q; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health (FBMH), University of Manchester, UK.
  • Zhang W; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health (FBMH), University of Manchester, UK.
  • Chen F; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health (FBMH), University of Manchester, UK.
  • Li S; Wellcome Centre for Cell-Matrix Research, School of Biological Sciences, FBMH, University of Manchester, UK.
  • Wang J; Department of Cancer Biology, Dana-Farber Cancer Institute, and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, USA.
  • Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, USA.
  • Risa-Ebrí B; Division of Pharmacy and Optometry, School of Health Sciences, FBMH, University of Manchester, UK.
  • Finegan KG; Division of Pharmacy and Optometry, School of Health Sciences, FBMH, University of Manchester, UK.
  • Cross MJ; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology (ISMIB), University of Liverpool, UK.
  • Giurisato E; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health (FBMH), University of Manchester, UK.
  • Whitmarsh AJ; Department of Biotechnology Chemistry and Pharmacy, University of Siena, Italy.
  • Tournier C; Division of Molecular and Cellular Function, School of Biological Sciences, FBMH, University of Manchester, UK.
Cancer Res Commun ; 2(3): 131-145, 2022 03 10.
Article en En | MEDLINE | ID: mdl-36466034
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Antineoplásicos Límite: Female / Humans Idioma: En Revista: Cancer Res Commun Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Antineoplásicos Límite: Female / Humans Idioma: En Revista: Cancer Res Commun Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido